S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
NASDAQ:DRIO

DarioHealth (DRIO) Stock Forecast, Price & News

$3.90
+0.06 (+1.56%)
(As of 05/31/2023 ET)
Compare
Today's Range
$3.81
$4.00
50-Day Range
$3.20
$4.12
52-Week Range
$3.13
$7.69
Volume
86,054 shs
Average Volume
151,479 shs
Market Capitalization
$102.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.40

DarioHealth MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
192.3% Upside
$11.40 Price Target
Short Interest
Bearish
7.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.87) to ($1.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.46 out of 5 stars

Medical Sector

940th out of 1,006 stocks

Surgical & Medical Instruments Industry

95th out of 104 stocks


DRIO stock logo

About DarioHealth (NASDAQ:DRIO) Stock

DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. Its solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

Receive DRIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DarioHealth and its competitors with MarketBeat's FREE daily newsletter.

DRIO Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
DarioHealth Q1 2023 Earnings Preview
LifeSci Capital Sticks to Their Buy Rating for DarioHealth (DRIO)
See More Headlines
Receive DRIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DarioHealth and its competitors with MarketBeat's FREE daily newsletter.

DRIO Company Calendar

Last Earnings
3/09/2023
Today
5/31/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DRIO
Employees
200
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$11.40
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+196.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-62,190,000.00
Net Margins
-125.46%
Pretax Margin
-221.65%

Debt

Sales & Book Value

Annual Sales
$27.66 million
Book Value
$2.73 per share

Miscellaneous

Free Float
23,883,000
Market Cap
$101.22 million
Optionable
Not Optionable
Beta
1.35

Social Links


Key Executives

  • Erez RaphaelErez Raphael
    Chief Executive Officer & Director
  • Richard Allen Anderson
    President & General Manager-North America Region
  • Joshua Fischer
    SVP-Operations & Compliance
  • Zvi Ben-David
    Chief Financial Officer, Secretary & Treasurer
  • Michal Hershkovitz
    Vice President-Clinical, Regulatory Affairs & QA













DRIO Stock - Frequently Asked Questions

Should I buy or sell DarioHealth stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DRIO shares.
View DRIO analyst ratings
or view top-rated stocks.

What is DarioHealth's stock price forecast for 2023?

4 equities research analysts have issued 1-year price targets for DarioHealth's shares. Their DRIO share price forecasts range from $6.00 to $15.00. On average, they expect the company's stock price to reach $11.40 in the next year. This suggests a possible upside of 196.9% from the stock's current price.
View analysts price targets for DRIO
or view top-rated stocks among Wall Street analysts.

How have DRIO shares performed in 2023?

DarioHealth's stock was trading at $4.28 at the beginning of 2023. Since then, DRIO stock has decreased by 10.3% and is now trading at $3.84.
View the best growth stocks for 2023 here
.

Are investors shorting DarioHealth?

DarioHealth saw a increase in short interest in May. As of May 15th, there was short interest totaling 2,040,000 shares, an increase of 9.7% from the April 30th total of 1,860,000 shares. Based on an average trading volume of 161,100 shares, the short-interest ratio is presently 12.7 days.
View DarioHealth's Short Interest
.

When is DarioHealth's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our DRIO earnings forecast
.

How were DarioHealth's earnings last quarter?

DarioHealth Corp. (NASDAQ:DRIO) announced its earnings results on Thursday, March, 9th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.09. The firm earned $6.81 million during the quarter, compared to the consensus estimate of $6.65 million. DarioHealth had a negative trailing twelve-month return on equity of 39.28% and a negative net margin of 125.46%. During the same quarter in the previous year, the business earned ($1.09) earnings per share.

What other stocks do shareholders of DarioHealth own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DarioHealth investors own include Aeterna Zentaris (AEZS), Vascular Biogenics (VBLT), Nano Dimension (NNDM), Pluristem Therapeutics (PSTI), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), ADMA Biologics (ADMA) and Avadel Pharmaceuticals (AVDL).

What is DarioHealth's stock symbol?

DarioHealth trades on the NASDAQ under the ticker symbol "DRIO."

Who are DarioHealth's major shareholders?

DarioHealth's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Appian Way Asset Management LP (3.88%), Perceptive Advisors LLC (1.19%), BlackRock Inc. (0.57%), MAI Capital Management (0.56%), Susquehanna International Group LLP (0.23%) and Renaissance Technologies LLC (0.22%). Insiders that own company stock include Dennis M Mcgrath, Dror Bacher, Erez Raphael and Oded Cohen.
View institutional ownership trends
.

How do I buy shares of DarioHealth?

Shares of DRIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DarioHealth's stock price today?

One share of DRIO stock can currently be purchased for approximately $3.84.

How much money does DarioHealth make?

DarioHealth (NASDAQ:DRIO) has a market capitalization of $101.22 million and generates $27.66 million in revenue each year. The company earns $-62,190,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.

How many employees does DarioHealth have?

The company employs 200 workers across the globe.

Does DarioHealth have any subsidiaries?
The following companies are subsidiares of DarioHealth: Labstyle Innovation Ltd., PsyInnovations Inc., PsyInnovations India Private Limited., Upright Technologies Inc., and Upright Technologies Ltd..
Read More
How can I contact DarioHealth?

DarioHealth's mailing address is 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900. The official website for the company is www.mydario.com. The company can be reached via phone at (833) 914-3796, via email at ir@mydario.com, or via fax at 972-4770-4059.

This page (NASDAQ:DRIO) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -